Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis

Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis

ABSTRACT Objective To assess safety of the switch between natalizumab and fingolimod without a washout period. Methods Prospective data on 25 JCV positive patients who underwent this medication switch were collected and analyzed. Results After a median period of nine months from the medication...

Full description

Bibliographic Details
Main Authors: Yara Dadalti Fragoso, Soniza Vieira Alves-Leon, Jefferson Becker, Joseph Bruno Bidin Brooks, Eber Castro Correa, Alfredo Damasceno, Paulo Diniz da Gama, Rodrigo Assad da Gama, Andre Palma da Cunha Matta, Ernane Pires Maciel, Thereza Cristina d’Avila Winckler
Format: Article
Language:English
Published: Academia Brasileira de Neurologia (ABNEURO) 2016-08-01
Series:Arquivos de Neuro-Psiquiatria
Subjects:
esclerose múltipla
natalizumab
cloridrato de fingolimode
terapêutica
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2016000800650&lng=en&tlng=en

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2016000800650&lng=en&tlng=en

Similar Items